Last10K.com

Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Aclaris Therapeutics, Inc.

CIK: 1557746 Ticker: ACRS

Exhibit 99.1

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Clinical and Commercial Developments

·

Initiates Financial Guidance for Full Year 2018

·

Management to Host Conference Call at 8:00 AM ET today

 

 

Wayne, PA – March 12, 2018 (GLOBE NEWSWIRE) –

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology, today announced financial results for the fourth quarter and year ended December 31, 2017 and provided an update on its clinical development and commercial programs.   

“2017 was a defining year in Aclaris’ history, with the FDA approval of ESKATA™ (hydrogen peroxide) Topical Solution, 40% (w/w),  the first and only FDA-approved topical, non-invasive treatment of raised seborrheic keratosis (SK). We  have generated a high level of excitement around ESKATA in the dermatology community, and look forward to our official launch in the second quarter of 2018,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris. “In January 2018, we announced positive topline results from two Phase 2 clinical trials (WART-202 and WART-203) of A-101 45% Topical Solution (A-101 45%) for the treatment of common warts (verruca vulgaris). We also advanced our topical Janus kinase (JAK) inhibitor programs in alopecia, with results from multiple Phase 2 trials expected later this year. As our early-stage pipeline compounds advance towards the clinic, we continue to progress towards our goal of becoming a vertically integrated, commercial-stage biopharmaceutical company with a robust clinical-stage pipeline and drug discovery engine.”

 

Clinical Pipeline Update

 

·

A-101 45% Topical Solution

o

In January 2018, reported positive results from two Phase 2 clinical trials (WART-202 and WART-203) of A-101 45%, an investigational new drug for the treatment of common warts. A-101 45% met all primary, secondary, and exploratory endpoints of each trial analyzed to date, achieving clinically and statistically significant clearance of common warts.

o

Scheduled an End of Phase 2 meeting with the FDA for mid-2018, and plan to initiate two pivotal Phase 3 trials in the second half of 2018.

·

JAK Inhibitor

o

AA-202 Topical – an ongoing Phase 2 clinical trial of ATI-502 (formerly ATI-50002) for the topical treatment of alopecia areata (AA). This trial will evaluate the pharmacokinetics,

 


The following information was filed by Aclaris Therapeutics, Inc. (ACRS) on Monday, March 12, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aclaris Therapeutics, Inc..

Continue

Assess how Aclaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Convertible Preferred Stock And Stockholders' Equity
Consolidated Statement Of Convertible Preferred Stock And Stockholders' Equity (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Operations And Comprehensive Loss (parenthetical)
401(k) Savings Plan
401(k) Savings Plan (details)
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Agreements Related To Intellectual Property
Agreements Related To Intellectual Property (details)
Commitments And Contingencies
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Confluence Acquisition
Confluence Acquisition (tables)
Confluence Acquisition - Fair Value Of Assets Acquired And Liabilities Assumed (details)
Confluence Acquisition - Summary Of Fair Value Consideration (details)
Confluence Acquisition - Supplemental Pro Forma Financial Information (details)
Fair Value Of Financial Assets And Liabilities
Fair Value Of Financial Assets And Liabilities (detail)
Fair Value Of Financial Assets And Liabilities (tables)
Fair Value Of Financial Assets And Liabilities - By Type (details)
Income Taxes
Income Taxes (tables)
Income Taxes - Deferred Assets And Liabilities, Cfds (details)
Income Taxes - Rate Reconciliation (details)
Income Taxes - Tax Cuts And Jobs Act (details)
Income Taxes - Valuation Allowance And Unrecognized Benefits (details)
Net Loss Per Share
Net Loss Per Share (details)
Net Loss Per Share (tables)
Net Loss Per Share - Anti-dilution (details)
Organization And Nature Of Business
Organization And Nature Of Business (details)
Property And Equipment, Net
Property And Equipment, Net (details)
Property And Equipment, Net (tables)
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited) (details)
Quarterly Financial Information (unaudited) (tables)
Related Party Transactions
Related Party Transactions (details)
Related Party Transactions (tables)
Segment Information
Segment Information (details)
Segment Information (tables)
Stock-based Awards
Stock-based Awards (details)
Stock-based Awards (tables)
Stock-based Awards - Compensation (details)
Stock-based Awards - Option Activity (details)
Stock-based Awards - Rsus (details)
Stockholders' Equity
Stockholders' Equity (details)
Stockholders' Equity - Ipo, Etc. (details)
Stockholders' Equity - Restricted Stock (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies - Deferred Costs, Etc. (details)
Summary Of Significant Accounting Policies - Risk (details)
Ticker: ACRS
CIK: 1557746
Form Type: 10-K Annual Report
Accession Number: 0001558370-18-001866
Submitted to the SEC: Mon Mar 12 2018 8:18:20 AM EST
Accepted by the SEC: Mon Mar 12 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acrs/0001558370-18-001866.htm